Literature DB >> 33407344

Ranking facilitators and barriers of medication adherence by patients with inflammatory arthritis: a maximum difference scaling exercise.

M J H Voshaar1, J E Vriezekolk2, A M van Dulmen3,4,5, B J F van den Bemt6,7,8, M A F J van de Laar9.   

Abstract

INTRODUCTION: Facilitators and barriers of adherence to disease-modifying anti-rheumatic drugs (DMARDs) have been identified by patients with inflammatory arthritis earlier. However, the relative importance from the patients' perspective of these factors is unknown. Knowledge on this ranking might guide the development of interventions and may facilitate targeted communication on adherence. This study aims to examine 1) the relative importance patients attach to facilitators and barriers for DMARDs adherence, and 2) the relationship between patient characteristics and ranking of these factors.
METHODS: One hundred twenty-eight outpatients with inflammatory arthritis; (60% female, mean age 62 years (SD = 12), median disease duration 15 years, IQR (7, 23) participated in a Maximum Difference scaling exercise and ranked 35 items based upon previously identified facilitators and barriers to medication adherence. Hierarchical Bayes estimation was used to compute mean Rescaled Probability Scores (RPS; 0-100) (i.e. relative importance score). Kendall's coefficient of concordance was used to examine a possible association between patients' characteristics (i.e. age, sex and educational level) and ranking of the items.
RESULTS: The three most important items ranked by patients were: Reduction of symptoms formulated as "Arthritis medications help to reduce my symptoms" (RPS = 7.30, CI 7.17-7.44), maintaining independence formulated as "I can maintain my independence as much as possible" (RPS = 6.76, CI 6.54-6.97) and Shared decision making formulated as "I can decide -together with my physician- about my arthritis medications" (RPS = 6.48, CI 6.24-6.72). No associations between patient characteristics and ranking of factors were found.
CONCLUSIONS: Reducing symptoms, maintaining independency and shared decision making are patients' most important factors for DMARDs adherence. This knowledge might guide the development of interventions and may facilitate communication between health professionals and their patients on medication adherence.

Entities:  

Keywords:  Best-worst scaling; DMARDs use; Inflammatory arthritis; MaxDiff; Medication adherence; Rheumatoid arthritis

Mesh:

Substances:

Year:  2021        PMID: 33407344      PMCID: PMC7786955          DOI: 10.1186/s12891-020-03874-2

Source DB:  PubMed          Journal:  BMC Musculoskelet Disord        ISSN: 1471-2474            Impact factor:   2.362


  37 in total

1.  Arthritis patients' motives for (not) wanting to be involved in medical decision-making and the factors that hinder or promote patient involvement.

Authors:  Ingrid Nota; Constance H C Drossaert; Erik Taal; Mart A F J van de Laar
Journal:  Clin Rheumatol       Date:  2014-11-14       Impact factor: 2.980

Review 2.  Motivational Interviewing Improves Medication Adherence: a Systematic Review and Meta-analysis.

Authors:  Ana Palacio; Desiree Garay; Benjamin Langer; Janielle Taylor; Barbara A Wood; Leonardo Tamariz
Journal:  J Gen Intern Med       Date:  2016-05-09       Impact factor: 5.128

3.  Rheumatoid arthritis patients and rheumatologists approach the decision to escalate care differently: results of a maximum difference scaling experiment.

Authors:  L T C van Hulst; W Kievit; R van Bommel; P L C M van Riel; L Fraenkel
Journal:  Arthritis Care Res (Hoboken)       Date:  2011-10       Impact factor: 4.794

4.  Patient and caregiver priorities for medication adherence in gout, osteoporosis and rheumatoid arthritis: nominal group technique.

Authors:  Ayano Kelly; Kathleen Tymms; Maarten de Wit; Susan J Bartlett; Marita Cross; Therese Dawson; Mary De Vera; Vicki Evans; Michael Gill; Geraldine Hassett; Irwin Lim; Karine Manera; Gabor Major; Lyn March; Sean O'Neill; Marieke Scholte-Voshaar; Premarani Sinnathurai; Daniel Sumpton; Armando Teixeira-Pinto; Peter Tugwell; Bart van den Bemt; Allison Tong
Journal:  Arthritis Care Res (Hoboken)       Date:  2019-07-19       Impact factor: 4.794

5.  Compliance to drug treatment of patients with rheumatoid arthritis: a 3 year longitudinal study.

Authors:  F Viller; F Guillemin; S Briançon; T Moum; T Suurmeijer; W van den Heuvel
Journal:  J Rheumatol       Date:  1999-10       Impact factor: 4.666

6.  The predictors of and reasons for non-adherence in an observational cohort of patients with rheumatoid arthritis commencing methotrexate.

Authors:  Holly F Hope; Kimme L Hyrich; James Anderson; James Bluett; Jamie C Sergeant; Anne Barton; Lis Cordingley; Suzanne M M Verstappen
Journal:  Rheumatology (Oxford)       Date:  2020-01-01       Impact factor: 7.580

Review 7.  Medication adherence of patients with selected rheumatic conditions: a systematic review of the literature.

Authors:  Leslie R Harrold; Susan E Andrade
Journal:  Semin Arthritis Rheum       Date:  2008-03-12       Impact factor: 5.532

8.  Adherence rates and associations with nonadherence in patients with rheumatoid arthritis using disease modifying antirheumatic drugs.

Authors:  Bart J F van den Bemt; Frank H J van den Hoogen; Bart Benraad; Yechiel A Hekster; Piet L C M van Riel; Wim van Lankveld
Journal:  J Rheumatol       Date:  2009-09-01       Impact factor: 4.666

Review 9.  EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update.

Authors:  Josef S Smolen; Robert Landewé; Johannes Bijlsma; Gerd Burmester; Katerina Chatzidionysiou; Maxime Dougados; Jackie Nam; Sofia Ramiro; Marieke Voshaar; Ronald van Vollenhoven; Daniel Aletaha; Martin Aringer; Maarten Boers; Chris D Buckley; Frank Buttgereit; Vivian Bykerk; Mario Cardiel; Bernard Combe; Maurizio Cutolo; Yvonne van Eijk-Hustings; Paul Emery; Axel Finckh; Cem Gabay; Juan Gomez-Reino; Laure Gossec; Jacques-Eric Gottenberg; Johanna M W Hazes; Tom Huizinga; Meghna Jani; Dmitry Karateev; Marios Kouloumas; Tore Kvien; Zhanguo Li; Xavier Mariette; Iain McInnes; Eduardo Mysler; Peter Nash; Karel Pavelka; Gyula Poór; Christophe Richez; Piet van Riel; Andrea Rubbert-Roth; Kenneth Saag; Jose da Silva; Tanja Stamm; Tsutomu Takeuchi; René Westhovens; Maarten de Wit; Désirée van der Heijde
Journal:  Ann Rheum Dis       Date:  2017-03-06       Impact factor: 19.103

10.  Preferences of patients with rheumatoid arthritis regarding disease-modifying antirheumatic drugs: a discrete choice experiment.

Authors:  Milou van Heuckelum; Elke Ge Mathijssen; Marcia Vervloet; Annelies Boonen; Renske Cf Hebing; Annelieke Pasma; Harald E Vonkeman; Mark H Wenink; Bart Jf van den Bemt; Liset van Dijk
Journal:  Patient Prefer Adherence       Date:  2019-07-22       Impact factor: 2.711

View more
  2 in total

1.  Are We on the Same Page?: A Cross-Sectional Study of Patient-Clinician Goal Concordance in Rheumatoid Arthritis.

Authors:  Jennifer L Barton; Sheila Markwardt; Meike Niederhausen; Allison Schue; Jacob Dougherty; Patricia Katz; Somnath Saha; Edward H Yelin
Journal:  Arthritis Care Res (Hoboken)       Date:  2021-09-27       Impact factor: 4.794

2.  Healthcare professionals' perceptions on barriers and facilitators to DMARD use in rheumatoid arthritis.

Authors:  M J H Voshaar; B J F van den Bemt; M A F J van de Laar; A M van Dulmen; J E Vriezekolk
Journal:  BMC Health Serv Res       Date:  2022-01-13       Impact factor: 2.655

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.